Literature DB >> 7402798

Efficacy of a 12-hour sustained-release preparation in maintaining therapeutic serum theophylline levels in asthmatic children.

H W Kelly, S Murphy.   

Abstract

The purpose of this study was to determine whether a new sustained-release theophylline preparation TheoDur could maintain therapeutic serum theophylline levels in asthmatic children on a 12-hour dosage regimen. Twenty asthmatic children aged 6 to 18 years with a mean of 11.4 years who required continuous theophylline therapy for control of their asthma were enrolled in the study. Each patient's dosage was titrated to achieve a six-hour postdose serum theophylline level between 10 and 20 microgram/ml. The patients required a mean +/- SEM dose of 10.0 +/- 0.54 mg/kg every 12 hours which gave a mean +/- SEM six-hour postdose serum theophylline level of 15.65 +/- 0.72 microgram/ml. At the end of five days on this dosage, the patients were admitted and serum theophylline levels were determined every three hours for 24 hours. The mean +/- SEM difference between maximum and minimum serum theophylline levels (delta TL) for the group was 4.5 +/- 0.3 microgram/ml. There was not a significant difference in the delta TL between the two age groups (6 to 9 years, 4.5 +/- 0.5 microgram/ml and 10 to 18 years 4.5 +/- 0.4 microgram/ml). In conclusion, TheoDur will maintain therapeutic serum theophylline levels with minimal fluctuations in asthmatic children on a 12-hour dosing schedule.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7402798

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences.

Authors:  M Lagas; J H Jonkman
Journal:  Pharm Weekbl Sci       Date:  1985-02-22

2.  Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.

Authors:  D R Taylor; D Duffin; C D Kinney; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

3.  Investigation of diurnal changes in the disposition of theophylline.

Authors:  D R Taylor; D Duffin; C D Kinney; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

4.  Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Authors:  Y Horai; T Ishizaki; T Sasaki; K Chiba; T Suganuma; H Echizen; A Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Bioavailability and pharmacokinetics of theophylline following plain uncoated and sustained-release dosage forms in relation to smoking habit. II. Multiple dose study.

Authors:  T Ishizaki; Y Horai; T Sasaki; K Chiba; A Ohnishi; T Suganuma; G Tsujimoto; H Echizen; T Okaniwa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Once a day theophylline; serum concentrations.

Authors:  V Nerminathan; S A McKenzie
Journal:  Arch Dis Child       Date:  1984-08       Impact factor: 3.791

Review 7.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

8.  Food induced changes in theophylline absorption from a once-a-day theophylline product.

Authors:  G Steffensen; S Pedersen
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

9.  Spiramycin has no effect on serum theophylline in asthmatic patients.

Authors:  D Debruyne; A Jehan; M C Bigot; B Lechevalier; J N Prevost; M Moulin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.

Authors:  J H Jonkman; W J van der Boon; L P Balant; R Schoenmaker; A Holtkamp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.